Equities

Verici DX PLC

VRCI:LSE

Verici DX PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3.50
  • Today's Change0.00 / 0.00%
  • Shares traded135.13k
  • 1 Year change-48.15%
  • Beta0.6427
Data delayed at least 20 minutes, as of Oct 31 2024 12:58 BST.
More ▼

Profile data is unavailable for this security.

About the company

Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.

  • Revenue in GBP (TTM)3.34m
  • Net income in GBP-3.71m
  • Incorporated2020
  • Employees19.00
  • Location
    Verici DX PLC393 Nichol Mill Lane, Suite 200FRANKLIN 37067United StatesUSA
  • Websitehttps://vericidx.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Deltex Medical Group plc1.78m-1.29m1.99m37.001.99m37.00
Aptamer Group PLC860.00k-2.96m4.32m54.004.32m54.00
Image Scan Holdings Plc2.56m-11.06k4.52m14.004.52m14.00
Surgical Innovations Group Plc12.54m-622.00k5.13m101.005.13m101.00
Feedback plc886.00k-3.49m6.47m24.006.47m24.00
Myhealthchecked PLC9.39m-1.04m6.63m10.006.63m10.00
Rua Life Sciences PLC2.19m-1.44m7.14m33.007.14m33.00
Genincode PLC2.60m-5.94m7.34m36.007.34m36.00
Cambridge Nutritional Sciences PLC9.77m-328.00k7.73m94.007.73m94.00
Proteome Sciences plc4.04m-4.08m8.15m35.008.15m35.00
Verici DX PLC3.34m-3.71m8.52m19.008.52m19.00
Data as of Oct 31 2024. Currency figures normalised to Verici DX PLC's reporting currency: UK Pound GBX

Institutional shareholders

36.45%Per cent of shares held by top holders
HolderShares% Held
Harwood Capital LLPas of 20 Feb 202437.65m15.52%
Octopus Investments Ltd.as of 20 Feb 202421.65m8.92%
Unicorn Asset Management Ltd.as of 30 Sep 202420.35m8.39%
Canaccord Genuity Wealth Ltd.as of 31 Mar 20246.93m2.86%
Dowgate Wealth Ltd.as of 30 Sep 20241.84m0.76%
Dimensional Fund Advisors Ltd.as of 31 Aug 20243.29k0.00%
Dimensional Fund Advisors LPas of 30 Jun 2024760.000.00%
Schroder Investment Management Ltd.as of 15 Feb 20240.000.00%
More ▼
Data from 30 Jun 2024 - 24 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.